All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On September 27th daratumumab was granted approval in Japan to treat patients with Relapsed or Refractory Multiple Myeloma (RRMM). Approval was granted by the Ministry of Health, Labor and Welfare (MHLW) for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone. This will be welcome news in a country where MM is one of the most common forms of blood cancer.
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule. In 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab. Consequently, upon the first commercial sale in Japan, Genmab will receive milestone payments from Janssen of $25 million.
The decision was based on data from two pivotal phase III clinical trials – POLLUX and CASTOR. The results of these studies also influenced approval by the European Medicines Agency (EMA) in April this year, for the same indication. In the US, the approval is wider as daratumumab is also licensed for use in combination pomalidomide and dexamethasone (see previous MM Hub article) for patients that have received at least two prior therapies. In addition, both the US Food and Drug Administration (FDA) and EMA have approved its use as a monotherapy for RRMM patients whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Subscribe to get the best content related to multiple myeloma delivered to your inbox